Filters
Results 1 - 10 of 6414
Results 1 - 10 of 6414.
Search took: 0.044 seconds
Sort by: date | relevance |
AbstractAbstract
[en] The strategy of treatment of Hodgkin and non-Hodgkin lymphomas is highlighted and the role of radiotherapy in the treatment discussed. (P.A.)
Original Title
Uloha radioterapie v lecbe malignich lymfomu
Primary Subject
Source
Ceska onkologicka spolecnost (Czech Republic); 38 p; 1997; p. 25-27; 3. South-Bohemian Oncology Days; 3. Jihoceske Onkologicke Dny; Cesky Krumlov (Czech Republic); 18-19 Oct 1996; 6 tabs.
Record Type
Miscellaneous
Literature Type
Conference
Report Number
Country of publication
Reference NumberReference Number
Related RecordRelated Record
INIS VolumeINIS Volume
INIS IssueINIS Issue
AbstractAbstract
[en] The proceedings of the workshop contain 16 contributions, out of which 3 have been input to INIS. (P.A.)
Original Title
III. Jihoceske Onkologicke Dny
Primary Subject
Source
1997; 38 p; 3. South-Bohemian Oncology Days; 3. Jihoceske Onkologicke Dny; Cesky Krumlov (Czech Republic); 18-19 Oct 1996
Record Type
Miscellaneous
Literature Type
Conference
Report Number
Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
AbstractAbstract
[en] In 1980, on the basis of fundamental and clinical data, a protocol was developed at the Institut Gustave-Roussy, alternating eight monthly courses of chemotherapy (CHVP) and two or three radiotherapy sequences to treat non-Hodgkin's lymphomas of unfavourable histologies, mainly stage II, presenting bulky tumours. Systemic, haematological and digestive tolerances were satisfactory. For 19 previously untreated stage II patients, overall survival and relapse-free survival after 30 months were 85 and 65%, respectively. Three of the relapses were observed in patients who did not receive the alternating schedule in an optimal way; this suggests that these results can be further improved. (orig.)
Primary Subject
Source
33 refs.; 1 figure; 2 tabs.
Record Type
Journal Article
Journal
Radiotherapy and Oncology; ISSN 0167-8140;
; v. 3(2); p. 133-138

Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
AbstractAbstract
[en] From 1981 to 1986, 12 patients with Stage I and II diffuse large cell lymphoma of the mediastinum were treated with 4 or more cycles of multiagent chemotherapy and for nine patients this was followed by mediastinal irradiation. The response to treatment was assessed by three-dimensional volumetric analysis utilizing thoracic CT scans. The initial mean tumor volume of the five patients relapsing was 540 ml in contrast to an initial mean tumor volume of 360 ml for the seven patients remaining in remission. Of the eight patients in whom mediastinal lymphoma volumes could be assessed 1-2 months after chemotherapy prior to mediastinal irradiation, the three patients who have relapsed had volumes of 292, 92 and 50 ml (mean volume 145 ml) in contrast to five patients who have remained in remission with residual volume abnormalities of 4-87 ml (mean volume 32 ml). Four patients in prolonged remission with CT scans taken one year after treatment have been noted to have mediastinal tumor volumes of 0-28 ml with a mean value of 10 ml. This volumetric technique to assess the extent of mediastinal large cell lymphoma from thoracic CT scans appears to be a useful method to quantitate the amount of disease at presentation as well as objectively monitor response to treatment. 13 refs.; 2 figs.; 1 table
Primary Subject
Record Type
Journal Article
Journal
Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
AbstractAbstract
[en] To identify predictors of hypothyroidism after chemoradiation therapy for Hodgkin lymphoma (HL) and to compare outcomes after intensity modulated radiation therapy (IMRT) with those after 3-dimensional (3D) conformal radiation therapy (CRT).
Primary Subject
Source
S0360301618304954; Available from http://dx.doi.org/10.1016/j.ijrobp.2018.03.003; Copyright (c) 2018 Elsevier Inc. All rights reserved.; Country of input: International Atomic Energy Agency (IAEA)
Record Type
Journal Article
Journal
International Journal of Radiation Oncology, Biology and Physics; ISSN 0360-3016;
; CODEN IOBPD3; v. 101(3); p. 530-540

Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
Dominguez F, S.; Carrion G, J.R.; Garcia A, P.; Perez F, R.; Flores S, E.; Jara S, C.; Perez M, G.
Proceedings of the 2. Iberian-American Congress of Oncology1988
Proceedings of the 2. Iberian-American Congress of Oncology1988
AbstractAbstract
[en] Published in summary form only
Original Title
Terapia combinada CHOP + radioterapia
Primary Subject
Source
Sociedade Brasileira de Cancerologia, Salvador, BA (Brazil); 156 p; 1988; p. 11; 2. Iberian-American Congress of Oncology; Salvador, BA (Brazil); 9-14 Oct 1988
Record Type
Miscellaneous
Literature Type
Conference
Report Number
Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
AbstractAbstract
[en] Obatoclax is a clinical stage drug candidate that has been proposed to target and inhibit prosurvival members of the Bcl-2 family, and thereby contribute to cancer cell lethality. The insolubility of this compound, however, has precluded the use of many classical drug-target interaction assays for its study. Thus, a direct demonstration of the proposed mechanism of action, and preferences for individual Bcl-2 family members, remain to be established. Employing modified proteins and lipids, we recapitulated the constitutive association and topology of mitochondrial outer membrane Mcl-1 and Bak in synthetic large unilamellar liposomes, and measured bakdependent bilayer permeability. Additionally, cellular and tumor models, dependent on Mcl-1 for survival, were employed. We show that regulation of bilayer permeabilization by the tBid – Mcl-1 - Bak axis closely resemblesthe tBid - Bcl-XL - Bax model. Obatoclax rapidly and completely partitioned into liposomal lipid but also rapidly exchanged between liposome particles. In this system, obatoclax was found to be a direct and potent antagonist of liposome-bound Mcl-1 but not of liposome-bound Bcl-XL, and did not directly influence Bak. A 2.5 molar excess of obatoclax relative to Mcl-1 overcame Mcl-1-mediated inhibition of tBid-Bak activation. Similar results were found for induction of Bak oligomers by Bim. Obatoclax exhibited potent lethality in a cellmodel dependent on Mcl-1 for viability but not in cells dependent on Bcl-XL. Molecular modeling predicts that the 3-methoxy moiety of obatoclax penetrates into the P2 pocket of the BH3 binding site of Mcl-1. A desmethoxy derivative of obatoclax failed to inhibit Mcl-1 in proteoliposomes and did not kill cells whose survival depends on Mcl-1. Systemic treatment of mice bearing Tsc2"+"/"- Em-myc lymphomas (whose cells depend on Mcl-1 for survival) with obatoclax conferred a survival advantage compared to vehicle alone (median 31 days vs 22 days, respectively; p=0.003). In an Akt-lymphoma mouse model, the anti-tumor effects of obatoclax synergized with doxorubicin. Finally, treatment of the multiple myeloma KMS11 cell model (dependent on Mcl-1 for survival) with dexamethasone induced Bim and Bim-dependent lethality. As predicted for an Mcl-1 antagonist, obatoclax and dexamethasone were synergistic in this model. Taken together, these findings indicate that obatoclax is a potent antagonist of membranerestricted Mcl-1. Obatoclax represents an attractive chemical series to generate second generation Mcl-1 inhibitors
Primary Subject
Secondary Subject
Source
Available from http://dx.doi.org/10.1186/s12885-015-1582-5; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4522062; PMCID: PMC4522062; PMID: 26231047; PUBLISHER-ID: 1582; OAI: oai:pubmedcentral.nih.gov:4522062; Copyright (c) Nguyen et al. 2015; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.; Country of input: International Atomic Energy Agency (IAEA)
Record Type
Journal Article
Journal
BMC cancer (Online); ISSN 1471-2407;
; v. 15; vp

Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
External URLExternal URL
AbstractAbstract
[en] Between 1966 and 1988, 149 patients were treated with radiotherapy for localized extranodal lymphoma. The average total dose given was 39.8 Gy for low grade diseases and 48.7 Gy for all other disease. Of the 149 patients, 60 also received adjuvant chemotherapy. Twenty-four had low grade lymphoma, 109 had intermediate grade disease, and 16 had high grade disease, histologically. The distribution of histological grade and T/B phenotype varied with the primary site. Low grade lymphomas were found mainly in the orbit, and T-cell lymphomas were found in the nasal cavity and nasopharynx. The 5-year survival rates according to tumor location were 89 percent for oral cavity, 86 percent for paranasal sinus, 83 percent for thyroid, 69 percent for orbit, 47 percent for Waldeyer's ring (WAR), 44 percent for testis, 23 percent for CNS, 21 percent for oral cavity and 60 percent for other sites. Histological grade and T/B phenotype both had prognostic importance. Combined chemo-therapy significantly improved the survival rate only for disease with intermediate or high grade histology. Other prognostic factors according to the primary site were the bulk of lymph node for WAR disease, the radiation dose for CNS disease, bone erosion for orbital disease, stridor for disease of the thyroid, and the tumor stage for disease of both the testis and the thyroid. (author). 32 refs.; 1 fig.; 5 tabs
Primary Subject
Record Type
Journal Article
Journal
Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
AbstractAbstract
No abstract available
Primary Subject
Source
S0360301617340567; Available from http://dx.doi.org/10.1016/j.ijrobp.2017.10.043; Copyright (c) 2017 Elsevier Inc. All rights reserved.; Country of input: International Atomic Energy Agency (IAEA)
Record Type
Journal Article
Journal
International Journal of Radiation Oncology, Biology and Physics; ISSN 0360-3016;
; CODEN IOBPD3; v. 100(3); p. 547-548

Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
Divgi, Chaitanya, E-mail: chaitanya.divgi@uphs.upenn.edu
International Atomic Energy Agency, Industrial Applications and Chemistry Section, Vienna (Austria)2010
International Atomic Energy Agency, Industrial Applications and Chemistry Section, Vienna (Austria)2010
AbstractAbstract
No abstract available
Primary Subject
Source
Mar 2010; 37 p; Technical meeting on therapeutic radiopharmaceuticals; Vienna (Austria); 16-20 Nov 2009; Published as PowerPoint presentation only; Working material
Record Type
Report
Literature Type
Conference
Report Number
Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
1 | 2 | 3 | Next |